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Abstract
Background: Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation
results from the good documentation and the impressive ocular fundus pictures.
Case presentation: We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal
choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated
clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated
by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of
noncompliance.
Conclusions: The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high
myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and
peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment.
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Background
Multifocal choroiditis (MFC) with panuveitis is a rare,
recurrent white dot syndrome affecting myopic women
in their third to fourth decades. Symptoms include
blurred vision, photopsia, or scotoma [1]. Clinical find-
ings comprise vitritis and multiple, small, round, yellow-
ish lesions at the level of the retinal pigment epithelium
and choriocapillaris at the posterior pole and in the per-
iphery. The presence of anterior uveitis or vitritis seems
to have prognostic implications [2]. Characteristically
the lesions are hypofluorescent in fluorescein angiog-
raphy (FA) and indocyanine green angiography (ICGA)
[1]. During the course of the disease the lesions become
hyperpigmented [3]. Treatment encompasses systemic
or periocular steroids and immunosuppression. Secondary
choroidal neovascularization (CNV) occurs in 27 to 46 %
of cases [1, 3–6]. It can be treated by intravitreal anti-
vascular endothelial growth factor (VEGF) application,
laser photocoagulation, photodynamic therapy, or surgical
excision [3, 4].
We present a 3-year course of a young myopic white
woman with MFC and secondary CNV. The activity of
the disease was evaluated clinically by optical coherence
tomography (OCT; Stratus, Carl-Zeiss-Meditec, Inc.)
and FA. Intravitreal bevacizumab (2.5 mg/0.1 ml) was
injected after informed consent was given. Retreatment
depended on visual acuity (VA), OCT, and FA findings.
The educational merit of this case presentation results
from the good documentation and the impressive ocular
fundus pictures. In addition, it displays why diagnosis
can be difficult in the beginning and emphasizes the
therapeutic importance of systemic immunosuppression.
Case presentation
A 22-year-old white woman presented with decreased
VA and a central floater in her right eye (OD) for 2
weeks. Apart from bilateral high myopia of –14 diopter
ophthalmological, her general and family history were
unremarkable. Her Snellen VA was 20/32 in her OD and
20/20 in her left eye (OS). Her intraocular pressure was
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normotonic. Funduscopy revealed a myopic fundus
with lacquer crack and small macular hemorrhage in
her OD (Fig. 1a). OCT showed discrete subretinal fluid
suspicious for CNV. FA was consistent with CNV
(Fig. 2a). She did not show up for further examinations
for personal reasons.
She presented again 11 months later with a loss of VA
and floaters in her OD. In the meantime she had re-
ceived intravitreal bevacizumab (2.5 mg/0.1 ml) for CNV
in her OS elsewhere. Her VA was 20/200 in her OD and
20/32 in her OS. A clinical examination showed vitreous
cells and roundish yellow to gray chorioretinal lesions in
the central and midperipheral fundus bilaterally. A small
subretinal hemorrhage (Fig. 1b) was found in her OD
and macular fibrosis was found in her OS. In FA the
multiple lesions were hypofluorescent in early phase and
hyperfluorescent in late phase. A discrete macular leakage
corresponded to a subfoveal CNV in her OD (Fig. 2b).
Borreliosis, toxoplasmosis, and syphilis were ruled out
serologically. A clinical examination did not show any
evidence of tuberculosis or sarcoidosis and MFC with
panuveitis was diagnosed. A combined treatment of oral
steroids (prednisolone 60 mg daily administered orally,
tapered off gradually) and intravitreal bevacizumab in
her OD was started. Subsequently, cyclosporine was
administered orally. One month later VA in her OS
dropped to 20/100 with a corresponding late leakage
in FA which was compatible with CNV reactivation.
Bevacizumab was re-injected in her OS.
During the following 15 months the number of inflam-
matory lesions remained constant with ongoing pigmen-
tation (Fig. 1c) indicating absent active inflammation.
Her VA increased to 20/100 in her OD and 20/25 in her
OS. Systemic immunosuppression was discontinued.
However, 1 month and 7 months later CNV recurred in
her OS. Bevacizumab was re-injected twice. Three years
after her first presentation her VA was 20/40 in her OD
and 20/200 in her OS.
Conclusions
The case reported is of educational merit because of its
impressive ocular fundus pictures. In addition, it is re-
markable in terms of diagnostics because of the delayed
onset of peripheral lesions and the additional existence
of high myopia that made diagnosis of MFC difficult.
CNV in MFC occurs in 27 to 46 % of cases [1, 3–6] and
can be the first symptom [3]. MFC lesions may be clinic-
ally occult, which impedes clinical diagnosis in early
stages of the disease. At our patient’s presentation FA
revealed only discrete multifocal peripheral lesions, which
were clearly evident 11 months later. ICGA could have
been an additional diagnostic tool displaying hypofluores-
cent lesions that were not visible clinically or on FA.
The hypofluorescence is considered to represent non-
perfusion areas of the choriocapillaris [1]. Because of
the myopic fundus with lacquer cracks it was difficult
to diagnose CNV funduscopically. Late leakage in FA
was discrete. Spaide et al. stated that in some cases
Fig. 1 Representative fundus images of right eye. a Initially apart from lacquer cracks and a discrete hemorrhage no peripheral lesions are visible.
b Eleven months later, multiple yellow to gray lesions at the level of the retinal pigment epithelium occur at the posterior pole and
midperipherally. c On immunosuppression no additional lesions occur 14 months and (d) 37 months later. Instead, lesions become increasingly
hyperpigmented indicating cicatrization
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differentiation between active inflammatory lesions
and CNV may be impossible even with multimodal
imaging as both can cause infiltrative lesions with
breakdown of the blood-barrier [7]. Our patient’s re-
sponse to intravitreal bevacizumab confirmed the ex-
istence of CNV.
Treatment options for inflammation in MFC are oral,
periocular, or intraocular steroids along with immuno-
suppressive agents [6]. Our patient lacked systemic ther-
apy for the first 11 months because further examinations
were rejected. Therefore this case demonstrates that full
outbreak of disease with multiple lesions of the central
and peripheral fundus can develop without systemic
treatment. Notably these lesions remained asymptom-
atic. On treatment with prednisolone administered orally
and consecutive cyclosporine administered orally, her in-
flammation subsided illustrating the need of systemic
immunosuppression. The number of lesions stagnated
and a progressive pigmentation indicating cicatrization
occurred.
Our case shows that CNV reactivation may occur
despite effective immunosuppression, at least at the
beginning of therapy. Nevertheless, immunosuppression is
supposed to prevent CNV by reducing the inflammatory
stimulus for neo-angiogenesis [5, 8]. Before starting and
after cessation of systemic immunosuppression, CNV re-
curred at frequent intervals bilaterally. This emphasizes
the importance of long-term effective immunosuppression
and short-term control in MFC.
In our case secondary CNV responded to intravitreal
bevacizumab. This is in accordance with studies where
intravitreal anti-VEGF was beneficial for CNV secondary
to MFC in terms of effectivity and safety [3, 5, 6, 9, 10].
A small number of re-injections – two at OD and three
at OS over 3 years – were sufficient for CNV control.
This is consistent with the literature [3]. Other CNV
treatment approaches such as argon laser photocoagu-
lation, photodynamic therapy, and surgical excision
are regarded to be inferior [1, 3, 4, 10]. In accordance
with the literature, VA in our patient improved after
intravitreal bevacizumab applications and no adverse
events occurred [3].
In conclusion, MFC is a rare recurrent disease that
predominantly affects young myopic women. Therefore
a careful dilated fundus examination including the periph-
ery is mandatory in all myopic women with CNV. As
clinical diagnosis can be difficult, FA and ICGA are
recommended for suspect cases. CNV occurrence seems
to be associated with insufficient immunosuppression.
When CNV is present it can be treated effectively with
anti-VEGF therapy requiring only few re-injections.
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Fig. 2 Optical coherence tomography and fluorescein angiography images of the right eye (a) first presentation: retinal pigment epithelium
detachment on optical coherence tomography and discrete subretinal fluid can be detected. On fluorescein angiography discrete hyperfluorescence
with a discrete late leakage in terms of a choroidal neovascularization near to the lacquer crack is visible. Furthermore, fluorescein angiography reveals
discrete roundish hypofluorescent lesions, which are clinically unapparent (Fig. 1a) but correspond to future lesions. b Eleven months later:
hypofluorescent lesions have considerably increased in number and were hyperfluorescent in late phase fluorescein angiography. A discrete macular late
leakage is found in the right eye consistent with a reactivated choroidal neovascularization
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